Page 3 - Confidence Interval News Today

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

An analysis of the NIH's All of Us program finds no increased ILD risk with methotrexate in dermatomyositis.

An analysis of NHANES found aspirin's benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets.

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy...

A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.

1. In this randomized controlled trial, in patients with infarct-relate cardiogenic shock, death from any cause was lower in the group that received the microaxial flow pump compared to the group that received the standard care. 2. The composite safety endpoint occurred in more patients in the microaxial flow pump group than in the standard

A retrospective challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

1. In this randomized controlled trial, long-term beta-blockers did not impact all-cause mortality among patients with preserved left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) and early angiography. 2. Long-term beta-blocker therapy was not associated with a higher risk of adverse events compared to no beta-blocker. Evidence Rating Level: 1 (Excellent) Study